All In MedTech

FDA Clearance Tracker · P080025

MEDTRONIC INTERSTIM SACRAL NERVE STIMULATION THERAPY SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 14, 2011 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Mar 14, 2011

Approved

Time to decision

899 days

Received Sep 26, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P080025
Device name
MEDTRONIC INTERSTIM SACRAL NERVE STIMULATION THERAPY SYSTEM
Applicant location
Minneapolis, MN
Received
Sep 26, 2008
Decided
Mar 14, 2011
Decision
Approved
Supplements
350 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code QON

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE MEDTRONIC INTERSTIM THERAPY SYSTEM. THE DEVICE IS INDICATED FOR THE TREATMENT OF CHRONIC FECAL INCONTINENCE IN PATIENTS WHO HAVE FAILED OR COULD NOT TOLERATE MORE CONSERVATIVE TREATMENTS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code QON (Implanted electrical device intended for treatment of fecal incontinence).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.